Palomino Laboratories Inc. reported a net loss of $7.03 million for the nine months ended September 30, 2026, compared to a $2.42 million loss in the prior year, driven by a significant increase in R&D and G&A expenses. The company strengthened its balance sheet during the period, ending the quarter with $17.79 million in cash and cash equivalents.
Palomino Laboratories held its 2026 Annual Meeting of Stockholders on November 5, 2026. Shareholders elected three directors, ratified KNAV CPA LLP as the independent auditor, and approved an amendment to the 2025 Equity Incentive Plan to increase the share reserve to the greater of 10 million shares or 15% of outstanding common stock.
Palomino Laboratories M&A Deal with Vega Links, Inc.
Palomino Laboratories Inc. filed an amendment to provide historical audited financial statements and pro forma financial information following its acquisition of Vega Links, Inc. The acquisition was completed via a share exchange where Palomino issued 4,472,000 shares of common stock to acquire all outstanding shares of Vega Links, making it a wholly owned subsidiary.